Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis

Glenn J. Jaffe, Rex M. McCallum, Brenda Branchaud, Cindy Skalak, Zuhal Butuner, Paul Ashton

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: To investigate the safety and efficacy of a fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. Design: Noncomparative interventional case series, dose randomized, dose masked, prospective. Participants: Thirty-six eyes of 32 patients with a history of recurrent noninfectious posterior uveitis. Methods: Patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone acetonide intravitreal implant. Patients were observed every 4 to 6 weeks for the first 3 months and then every 3 months thereafter. Main Outcome Measures: Preoperative and postoperative ocular inflammation, visual acuity (VA), antiinflammatory medication use, and safety. Results: Mean follow-up duration was 683±461 days (range, 204-1817). Mean baseline visual acuity for the device-implanted eyes was +1.1 logarithm of the minimum angle of resolution (logMAR) units (20/250), which improved significantly to +0.81 logMAR units (20/125) at 30 months (P<0.05). Inflammation was effectively controlled over the follow-up period. The average number of recurrences in the 12 months before implantation was 2.5 episodes per eye. None of these eyes experienced a recurrence for the first 2 years after implantation. There was a reduction in systemic and local therapy use in the device-implanted eyes; of the patients who remained on systemic medication after implantation, dosage was reduced in 68%. The posterior sub-Tenon's capsule injection rate significantly decreased from a mean of 2.2 injections per eye per year to 0.07 injections per eye per year (P<0.0001) The most common adverse event was intraocular pressure (IOP) rise. At baseline, 11.0% of eyes used pressure-lowering agents, versus 56.1% over the follow-up period (P = 0.005). Filtering procedures were performed in 7 (19.4%) eyes. Four of the 8 phakic eyes, each of which had some level of cataract at device implantation, subsequently underwent cataract extraction. There were no device explantations or patients lost to follow-up during the investigation. Conclusion: The fluocinolone acetonide intravitreal implant effectively controlled intraocular inflammation in the studied population. Elevated IOP and cataracts that occurred in fluocinolone device-implanted eyes were managed by standard means. The fluocinolone acetonide sustained drug delivery implant seems to be promising in patients with posterior uveitis who do not respond to or are intolerant to conventional treatment.

Original languageEnglish (US)
JournalOphthalmology
Volume112
Issue number7
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Fluocinolone Acetonide
Posterior Uveitis
Equipment and Supplies
Inflammation
Intraocular Pressure
Cataract
Injections
Visual Acuity
Tenon Capsule
Drug Implants
Safety
Recurrence
Cataract Extraction
Lost to Follow-Up

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. / Jaffe, Glenn J.; McCallum, Rex M.; Branchaud, Brenda; Skalak, Cindy; Butuner, Zuhal; Ashton, Paul.

In: Ophthalmology, Vol. 112, No. 7, 07.2005.

Research output: Contribution to journalArticle

Jaffe, Glenn J. ; McCallum, Rex M. ; Branchaud, Brenda ; Skalak, Cindy ; Butuner, Zuhal ; Ashton, Paul. / Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. In: Ophthalmology. 2005 ; Vol. 112, No. 7.
@article{009455cc223043c0a3bededb4bf8072a,
title = "Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis",
abstract = "Purpose: To investigate the safety and efficacy of a fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. Design: Noncomparative interventional case series, dose randomized, dose masked, prospective. Participants: Thirty-six eyes of 32 patients with a history of recurrent noninfectious posterior uveitis. Methods: Patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone acetonide intravitreal implant. Patients were observed every 4 to 6 weeks for the first 3 months and then every 3 months thereafter. Main Outcome Measures: Preoperative and postoperative ocular inflammation, visual acuity (VA), antiinflammatory medication use, and safety. Results: Mean follow-up duration was 683±461 days (range, 204-1817). Mean baseline visual acuity for the device-implanted eyes was +1.1 logarithm of the minimum angle of resolution (logMAR) units (20/250), which improved significantly to +0.81 logMAR units (20/125) at 30 months (P<0.05). Inflammation was effectively controlled over the follow-up period. The average number of recurrences in the 12 months before implantation was 2.5 episodes per eye. None of these eyes experienced a recurrence for the first 2 years after implantation. There was a reduction in systemic and local therapy use in the device-implanted eyes; of the patients who remained on systemic medication after implantation, dosage was reduced in 68{\%}. The posterior sub-Tenon's capsule injection rate significantly decreased from a mean of 2.2 injections per eye per year to 0.07 injections per eye per year (P<0.0001) The most common adverse event was intraocular pressure (IOP) rise. At baseline, 11.0{\%} of eyes used pressure-lowering agents, versus 56.1{\%} over the follow-up period (P = 0.005). Filtering procedures were performed in 7 (19.4{\%}) eyes. Four of the 8 phakic eyes, each of which had some level of cataract at device implantation, subsequently underwent cataract extraction. There were no device explantations or patients lost to follow-up during the investigation. Conclusion: The fluocinolone acetonide intravitreal implant effectively controlled intraocular inflammation in the studied population. Elevated IOP and cataracts that occurred in fluocinolone device-implanted eyes were managed by standard means. The fluocinolone acetonide sustained drug delivery implant seems to be promising in patients with posterior uveitis who do not respond to or are intolerant to conventional treatment.",
author = "Jaffe, {Glenn J.} and McCallum, {Rex M.} and Brenda Branchaud and Cindy Skalak and Zuhal Butuner and Paul Ashton",
year = "2005",
month = "7",
doi = "10.1016/j.ophtha.2005.03.013",
language = "English (US)",
volume = "112",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis

AU - Jaffe, Glenn J.

AU - McCallum, Rex M.

AU - Branchaud, Brenda

AU - Skalak, Cindy

AU - Butuner, Zuhal

AU - Ashton, Paul

PY - 2005/7

Y1 - 2005/7

N2 - Purpose: To investigate the safety and efficacy of a fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. Design: Noncomparative interventional case series, dose randomized, dose masked, prospective. Participants: Thirty-six eyes of 32 patients with a history of recurrent noninfectious posterior uveitis. Methods: Patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone acetonide intravitreal implant. Patients were observed every 4 to 6 weeks for the first 3 months and then every 3 months thereafter. Main Outcome Measures: Preoperative and postoperative ocular inflammation, visual acuity (VA), antiinflammatory medication use, and safety. Results: Mean follow-up duration was 683±461 days (range, 204-1817). Mean baseline visual acuity for the device-implanted eyes was +1.1 logarithm of the minimum angle of resolution (logMAR) units (20/250), which improved significantly to +0.81 logMAR units (20/125) at 30 months (P<0.05). Inflammation was effectively controlled over the follow-up period. The average number of recurrences in the 12 months before implantation was 2.5 episodes per eye. None of these eyes experienced a recurrence for the first 2 years after implantation. There was a reduction in systemic and local therapy use in the device-implanted eyes; of the patients who remained on systemic medication after implantation, dosage was reduced in 68%. The posterior sub-Tenon's capsule injection rate significantly decreased from a mean of 2.2 injections per eye per year to 0.07 injections per eye per year (P<0.0001) The most common adverse event was intraocular pressure (IOP) rise. At baseline, 11.0% of eyes used pressure-lowering agents, versus 56.1% over the follow-up period (P = 0.005). Filtering procedures were performed in 7 (19.4%) eyes. Four of the 8 phakic eyes, each of which had some level of cataract at device implantation, subsequently underwent cataract extraction. There were no device explantations or patients lost to follow-up during the investigation. Conclusion: The fluocinolone acetonide intravitreal implant effectively controlled intraocular inflammation in the studied population. Elevated IOP and cataracts that occurred in fluocinolone device-implanted eyes were managed by standard means. The fluocinolone acetonide sustained drug delivery implant seems to be promising in patients with posterior uveitis who do not respond to or are intolerant to conventional treatment.

AB - Purpose: To investigate the safety and efficacy of a fluocinolone acetonide intravitreal implant in the treatment of noninfectious posterior uveitis. Design: Noncomparative interventional case series, dose randomized, dose masked, prospective. Participants: Thirty-six eyes of 32 patients with a history of recurrent noninfectious posterior uveitis. Methods: Patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone acetonide intravitreal implant. Patients were observed every 4 to 6 weeks for the first 3 months and then every 3 months thereafter. Main Outcome Measures: Preoperative and postoperative ocular inflammation, visual acuity (VA), antiinflammatory medication use, and safety. Results: Mean follow-up duration was 683±461 days (range, 204-1817). Mean baseline visual acuity for the device-implanted eyes was +1.1 logarithm of the minimum angle of resolution (logMAR) units (20/250), which improved significantly to +0.81 logMAR units (20/125) at 30 months (P<0.05). Inflammation was effectively controlled over the follow-up period. The average number of recurrences in the 12 months before implantation was 2.5 episodes per eye. None of these eyes experienced a recurrence for the first 2 years after implantation. There was a reduction in systemic and local therapy use in the device-implanted eyes; of the patients who remained on systemic medication after implantation, dosage was reduced in 68%. The posterior sub-Tenon's capsule injection rate significantly decreased from a mean of 2.2 injections per eye per year to 0.07 injections per eye per year (P<0.0001) The most common adverse event was intraocular pressure (IOP) rise. At baseline, 11.0% of eyes used pressure-lowering agents, versus 56.1% over the follow-up period (P = 0.005). Filtering procedures were performed in 7 (19.4%) eyes. Four of the 8 phakic eyes, each of which had some level of cataract at device implantation, subsequently underwent cataract extraction. There were no device explantations or patients lost to follow-up during the investigation. Conclusion: The fluocinolone acetonide intravitreal implant effectively controlled intraocular inflammation in the studied population. Elevated IOP and cataracts that occurred in fluocinolone device-implanted eyes were managed by standard means. The fluocinolone acetonide sustained drug delivery implant seems to be promising in patients with posterior uveitis who do not respond to or are intolerant to conventional treatment.

UR - http://www.scopus.com/inward/record.url?scp=21444461055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444461055&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2005.03.013

DO - 10.1016/j.ophtha.2005.03.013

M3 - Article

C2 - 15921758

AN - SCOPUS:21444461055

VL - 112

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 7

ER -